Table 4 In vivo worm burden reductions after a single oral dose of 200 mg/kg (afatinib) or 400 mg/kg body weight (remaining drugs) to mice harboring a chronic S.mansoni infection
From: Repurposing of anticancer drugs: in vitro and in vivo activities against Schistosoma mansoni
Drug | Number of mice treated | Average worm count (SD) | WBR [%] |
|---|---|---|---|
Control1 | 8 | 20.4 (12.4) | - |
Control2 | 8 | 23.0 (18.4) | - |
Trametinib1,2 | 5 | 8.1 (4.1) | 63.6 |
Vandetanib1,2 | 5 | 11.3 (8.4) | 48.1 |
Afatinib1 | 4 | 14.8 (11.1) | 27.5 |
Ponatinib1 | 3 | 16.6 (12.9) | 18.6 |
Sunitinib1 | 4 | 22.5 (8.5) | 2.2 |
Bosutinib1 | 4 | 25.3 (4.0) | 0 |